Home  »  Hot Stocks   »  Is There a Dimmer Outlook Ahead for Humanigen Inc....

Is There a Dimmer Outlook Ahead for Humanigen Inc. (HGEN)?

Humanigen Inc. (NASDAQ:HGEN) went down by -8.98% from its latest closing price compared to the recent 1-year high of $8.38. The company’s stock price has collected -24.46% of loss in the last five trading sessions. Barron’s reported on 09/09/21 that Humanigen Sinks After FDA Declines Covid Drug Emergency Use Request

Is It Worth Investing in Humanigen Inc. (NASDAQ :HGEN) Right Now?

Plus, the 36-month beta value for HGEN is at -1.05.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


HGEN currently public float of 89.42M and currently shorts hold a 4.47% ratio of that float. Today, the average trading volume of HGEN was 9.29M shares.

HGEN’s Market Performance

HGEN stocks went down by -24.46% for the week, with a monthly drop of -46.20% and a quarterly performance of -93.57%, while its annual performance rate touched -97.46%. The volatility ratio for the week stands at 8.27% while the volatility levels for the past 30 days are set at 7.45% for Humanigen Inc. The simple moving average for the period of the last 20 days is -29.44% for HGEN stocks with a simple moving average of -92.39% for the last 200 days.

Analysts’ Opinion of HGEN

Many brokerage firms have already submitted their reports for HGEN stocks, with ROTH Capital repeating the rating for HGEN by listing it as a “Neutral.” The predicted price for HGEN in the upcoming period, according to ROTH Capital is $2 based on the research report published on July 13th of the current year 2022.

Cantor Fitzgerald gave a rating of “Neutral” to HGEN, setting the target price at $2 in the report published on July 13th of the current year.

HGEN Trading at -57.89% from the 50-Day Moving Average

After a stumble in the market that brought HGEN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.07% of loss for the given period.

Volatility was left at 7.45%, however, over the last 30 days, the volatility rate increased by 8.27%, as shares sank -47.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -94.58% lower at present.

During the last 5 trading sessions, HGEN fell by -24.46%, which changed the moving average for the period of 200-days by -97.04% in comparison to the 20-day moving average, which settled at $0.2225. In addition, Humanigen Inc. saw -95.64% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at HGEN starting from Chappell Dale, who purchase 545,488 shares at the price of $2.23 back on May 20. After this action, Chappell Dale now owns 8,675,081 shares of Humanigen Inc., valued at $1,215,347 using the latest closing price.

Chappell Dale, the Chief Scientific Officer of Humanigen Inc., purchase 323,808 shares at $2.19 during a trade that took place back on May 19, which means that Chappell Dale is holding 8,293,240 shares at $707,844 based on the most recent closing price.

Stock Fundamentals for HGEN

Current profitability levels for the company are sitting at:

  • -6474.88 for the present operating margin

The net margin for Humanigen Inc. stands at -6582.73. Equity return is now at value 521.00, with -224.90 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 1.03.